The field of medicinal chemistry is constantly exploring novel molecular structures to develop more effective and targeted therapeutic agents. Among the diverse heterocyclic compounds, quinazoline derivatives have garnered significant attention due to their broad spectrum of biological activities and their presence in many approved drugs. A key example of such a derivative is 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (CAS 183322-18-1), a compound of considerable interest in pharmaceutical research and development.

Quinazoline, a bicyclic aromatic heterocycle, serves as a privileged scaffold in drug design. Its structure, composed of fused benzene and pyrimidine rings, allows for diverse substitutions that can significantly influence pharmacological properties. The specific derivative, 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, is notable for its role as an intermediate. The presence of a chlorine atom at the 4-position makes it reactive for nucleophilic substitution, a common strategy in organic synthesis for introducing various pharmacophores.

The significance of this compound is perhaps most evident in its application as an Erlotinib intermediate. Erlotinib, an EGFR tyrosine kinase inhibitor, is a vital medication in the treatment of certain cancers. The synthesis pathway for Erlotinib often involves the reaction of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline with other reagents to build the final complex molecular structure. This highlights why sourcing high-purity CAS 183322-18-1 is critical for consistent and effective drug manufacturing.

For researchers and procurement specialists, understanding the chemical properties of such intermediates is key. 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is typically available as a white powder, and its stability under appropriate storage conditions is crucial for maintaining its integrity. When you buy 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline, verifying its purity (often 99.0% or higher) is essential to prevent issues in downstream synthesis.

The demand for reliable access to these compounds drives the market for specialized chemical suppliers. Identifying a trusted pharmaceutical intermediate supplier or a dedicated 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline manufacturer ensures that research projects and production lines are not hampered by supply chain issues. Companies often look for competitive price for 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline from a reputable 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline supplier in China or globally.

Beyond Erlotinib, quinazoline derivatives continue to be explored for a wide range of therapeutic areas, including anti-cancer, anti-inflammatory, anti-microbial, and cardiovascular applications. The ability to readily procure and work with intermediates like 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is fundamental to this ongoing innovation in medicinal chemistry. Therefore, establishing strong relationships with suppliers who can guarantee the quality and availability of these essential chemical building blocks is a strategic imperative for any pharmaceutical research endeavor.